Shares in the Californian biopharmaceutical firm Nektar Therapeutics (Nasdaq: NKTR) went through the roof today on positive news from a pivotal trial of NKTR-181, the company’s opioid analgesic candidate.
Nektar announced that the therapy had met primary and secondary endpoints in the Phase III study, significantly reducing pain in patients with lower back pain.
NKTR-181 is a new chemical entity and the first full mu-opioid agonist designed to provide potent pain relief without the high levels of euphoria that can lead to abuse and addiction with standard opioids.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze